Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity
Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity
Overview
US cancer immunotherapy developer's Q2 collaboration revenue fell sharply from prior year
Net loss narrowed yr/yr on lower R&D and G&A expenses after restructuring
Company expects cash to fund operations into Q1 2027
Outlook
Bolt expects initial clinical data from BDC-4182 Phase 1/2 study with 3Q 2026 results
Company anticipates cash balance will fund operations into 1Q 2027
Result Drivers
LOWER EXPENSES - Co said R&D and G&A expenses declined mainly due to restructuring and reduced research activity
CLINICAL TRIAL PROGRESS - Co said ongoing BDC-4182 Phase 1/2 study in gastric and gastroesophageal cancer advanced to Cohort 4
Company press release: ID:nGNXBV9Qw
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Collaboration Revenue |
| $5,000 |
|
Q2 Net Loss |
| $7.72 mln |
|
Q2 Income from Operations |
| -$8.37 mln |
|
Q2 Loss Per Basic Share |
| $4.57 |
|
Q2 Operating Expenses |
| $8.38 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Bolt Biotherapeutics, Inc. is $7.00, about 75.4% above its August 10 closing price of $3.99
Reuters Recommended Reads
Aug 11 - Theriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Aug 11 - Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Aug 11 - Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)